Effect of simvastatin on the oxidation of native and modified lipoproteins

Biochemical Pharmacology

Volumn 70, Issue 8, 2005, Pages 1185-1191

  Sobal, Grazyna ^a   Sinzinger, Helmut ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Atherosclerosis; Glycation; Glycoxidation; Lipoproteins; Modified lipoproteins; Simvastatin; Statins

Indexed keywords

ALKADIENE; GLYCOSYLATED PROTEIN; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MALONALDEHYDE; OXIDIZED LOW DENSITY LIPOPROTEIN; SIMVASTATIN;

ADULT; ANTIOXIDANT ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONJUGATION; ELECTROPHORETIC MOBILITY; HUMAN; LIPID OXIDATION; NORMAL HUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ADULT; ELECTROPHORESIS, AGAR GEL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MIDDLE AGED; OXIDATION-REDUCTION; REFERENCE VALUES; SIMVASTATIN; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 24944436272     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2005.07.022     Document Type: Article

References (50)

1. C. Steiner Atherosclerosis, the major complication of diabetes Adv Exp Med Biol 189 1985 277 297
2. D. Steinberg, S. Parthasarathy, T.E. Carew, J.C. Khoo, and J.L. Witztum Beyond cholesterol: modification that increases its atherogenicity New Engl J Med 320 1989 915 924
3. C.P. Sparrow, S. Parthasarathy, and D. Steinberg Macrophage receptor that recognizes oxidized low-density lipoprotein but not acetylated low-density lipoprotein J Biol Chem 264 1989 2599 2604
4. G. Sobal, E.J. Menzel, and H. Sinzinger Why is glycated LDL more sensitive to oxidation than native LDL? - a comparative study Prostagl Leuk Essent Fatt Acids 63 2000 177 186
5. E.J. Menzel, G. Sobal, and A. Staudinger The role of oxidative stress in the long-term glycation of LDL BioFactors 6 1997 111 124
6. R. Bucala, Z. Makita, T. Koschinsky, A. Cerami, and H. Vlassara Lipid advanced glycosylation: pathway for lipid oxidation in-vivo Proc Natl Acad. Sci USA 90 1993 6434 6438
7. M. Farnier, and J. Davignon Current and future treatment of hyperlipidemia: the role of statins Am J Cardiol 82 1998 3J 10J
8. I. Hsu, S.A. Spinler, and N.E. Johnson Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia Ann Pharmacother 29 1995 743 759
9. H. Lennernäs, and G. Fager Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences Clin Pharmacokinet 32 1997 403 425
10. G.L. Plosker, and D. McTavish Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia Drugs 50 1995 334 363
11. J.P. Desager, and Y. Horsmans Clinical pharmacokinetics of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors Clin Pharmacokinet 31 1996 348 371
12. V.F. Mauro, and J.L. MacDonald Simvastatin: a review of its pharmacology and clinical use DICP 25 1991 257 264
13. T.R. Pedersen, and J.A. Tobert Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal Drug Saf 14 1996 11 24
14. P.A. Todd, and K.L. Goa Simvastatin. A review of its pharmacological properties and therapeutic potential in hypercholesterolaemia Drugs 40 1990 583 607
15. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). J Am Med Assoc 2001;285:2486-97.
16. P.R. de-Sauvage-Nolting, R.J. Buirma, B.A. Hutten, and J.J. Kastelein Baseline lipid values partly determine the response to high-dose simvastatin in patients with familial hypercholesterolemia. The examination of probands and relatives in statin studies with familial hypercholesterolemia Atherosclerosis 164 2002 347 354
17. P. Amarenco Hypercholesterolemia, lipid-lowering agents, and the risk for brain infarction Neurology 57 Suppl. 2 2001 S35 S44
18. T. Gordon, W.P. Castelli, M.C. Hjortland, W.B. Kannel, and T.R. Dawber High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study Am J Med 62 1977 707 714
19. G.M. Reaven, Y.D. Chen, J. Jeppesen, P. Maheux, and R.M.J. Krauss Insulin resistance and hyperinsulinemia in individuals with small, dense low density lipoprotein particles Clin Invest 92 1993 141 146
20. A. Von Eckardstein, J. Nofer, and G. Assmann High density lipoproteins and arteriosclerosis: role of cholesterol efflux and reverse cholesterol transport Arterioscler Thromb Vasc Biol 21 2001 13 17
21. P.O. Kwiterovich Jr. The metabolic pathways of high-density lipoprotein, low-density lipoprotein, and triglycerides: a current review Am J Cardiol 86 Suppl. 2000 5L 10L
22. J.P. Segrest, L. Li, G.M. Anantharamaiah, S.C. Harvey, K.N. Liadak, and V. Zannis Structure and function of apolipoprotein A-I and high density lipoprotein Curr Opin Lipidol 11 2000 106 115
23. C.R. Harper, and T.A. Jacobson New perspectives on the management of low levels of high-density lipoprotein cholesterol Arch Intern Med 159 1999 1049 1057
24. M.L. Kashyap Mechanism studies of high-density lipoproteins Am J Cardiol 82 1998 42U 48U
25. R. Alan Tall Plasma high density lipoproteins. Metabolism and relationship to atherogenesis J Clin Invest 86 1990 379 384
26. R.S. Rosenson, and C.C. Tangney Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction J Am Med Assoc 279 1998 1643 1650
27. H. Sinzinger, and A. Oguogho Variable influence of statins on isoprostanes in hyperlipidemia Adv Exp Med Biol 525 2003 209 212
28. M.J. Chapman, S. Goldstein, D. Lagrange, and P.M. Laplaud A density gradient ultracentrifugal procedure for the isolation of the major lipoprotein classes from human serum J Lipid Res 22 1981 339 358
29. H. Esterbauer, G. Striegl, H. Puhl, and M. Rotheneder Continuous monitoring of in vitro oxidation of human low density lipoprotein Free Radic Res Commun 6 1989 67 75
30. M. Ahotupa, J. Marniemi, T. Lehtimäke, K. Talvinen, O.T. Raitakari, and T. Vasankari Baseline diene conjugation in LDL lipids as a direct measure of in vivo LDL oxidation Clin Biochem 31 1998 257 261
31. J.A. Buege, and S.D. Aust Lactoperoxidase-catalyzed lipid peroxidation of microsomal and artificial membranes Biochim Biophys Acta 444 1976 192 201
32. S. Salmon, C. Maziere, M. Auclair, L. Theron, R. Santus, and J.C. Maziere Malondialdehyde modification and copper-induced autooxidation of high-density lipoprotein decrease cholesterol efflux from human cultured fibroblasts Biochim Biophys Acta 1125 1992 230 235
33. T. Matsunaga, T. Nakajima, T. Miyazaki, I. Koyama, S. Hokari, and I. Inoue Glycated high-density lipoprotein regulates reactive oxygen species and reactive nitrogen species in endothelial cells Metabolism 52 2003 42 49
34. A.E. La Ville, R. Sola, J. Balanya, P.R. Turner, and L. Masana In vitro oxidised HDL is recognized by the scavenger receptor of macrophages: implications for its protective role in vivo Atherosclerosis 105 1994 179 189
35. U. Christians, W. Jacobsen, and L.C. Floren Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: are the statins mechanistically similar? Pharmacol Ther 80 1998 1 34
36. V.F. Mauro Clinical pharmacokinetics and practical applications of simvastatin Clin Pharmacokinet 24 1993 195 202
37. G.L. Plosker, and D. McTavish Simvastatin. A reappraisal of its pharmacology and therapeutic efficacy in hypercholesterolaemia Drugs 50 1995 334 363
38. R.S. Rosenson Current overview of statin-induced myopathy Am J Med 116 2004 408 416
39. C. Steiner Atherosclerosis, the major complication of diabetes Adv Exp Med Biol 189 1985 277 297
40. R. Bucala, Z. Makita, G. Vega, S. Grundy, T. Koschinsky, and A. Cerami Modification of low density lipoprotein by advanced glycation end products contributes to the dyslipidemia of diabetes and renal insufficiency Proc Natl Acad Sci USA 91 1985 9441 9445
41. L. Cominacini, U. Garbin, and A.M. Pastorino Increased susceptibility of LDL to in vitro oxidation in patients with insulin-dependent and non-insulin-dependent diabetes mellitus Diab Res 26 1994 173 184
42. A. Ceriello, N. Bortolotti, M. Pirisi, A. Crescentini, L. Tonutti, and E. Motz Total plasma antioxidant capacity predicts thrombosis-prone status in NIDDM patients Diab Care 20 1997 1589 1593
43. V.V. Tertov, I.A. Sobenin, V.V. Kaplun, and A.N. Orekhov Antioxidant content in low density lipoprotein and lipoprotein oxidation in vivo and in vitro Free Radic Res 29 1998 165 173
44. K. Kjaer, J. Hangaard, N.E. Petersen, and C. Hagen Effect of simvastatin in patients with type I (insulin-dependent) diabetes mellitus and hypercholesterolemia Acta Endocrinol (Copenh) 126 1992 229 232
45. R.T. van Deursen, A.C. Nieuwenhuijzen-Kruseman, C.P. Degenaar, and B. Wolffenbuttel The effects of the cholesterol synthesis inhibitor simvastatin in patients with hypercholesterolemia with and without diabetes mellitus Ned Tijdschr Geneeskd 134 1990 2142 2146
46. G. Sobal, E.J. Menzel, and H. Sinzinger Influence of acetylsalicylic acid on oxidation of native and glycated low-density lipoprotein Life Sci 66 2000 1987 1998
47. G. Sobal, H. Sinzinger, and E.J. Menzel Troglitazone-binding to LDL and its glycated modifications: its role in cell-catalysed and Cu-mediated LDL-oxidation Life Sci 67 2000 695 707
48. G. Sobal, J. Menzel, and H. Sinzinger Calcium antagonists as inhibitors of in-vitro LDL-oxidation and glycation Biochem Pharmacol 61 2001 373 379
49. R. Liu, K. Saku, B. Zhang, K. Hirata, M. Shiomi, and K. Arakawa In vivo kinetics of oxidatively modified HDL Biochem Med Metab Biol 49 1993 392 397
50. G. Marsche, A. Hammer, O. Oskolkova, K.F. Kozarsky, W. Sattler, and E. Malle Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport J Biol Chem 277 2002 32172 32179